From seed to market; maintaining a sustainable capital market in the Nordics
Super Session 1 – Financing
Measured by the high level of business activities and the impressive number of companies, the Nordic life science sector is strong in an international context and has contributed to many innovations on the global market. Appropriate and timely financing is a must for the Nordic life science companies in order to progress the development of their respective project pipelines. This session highlights specific Nordic features such as the growing number of early to mid-stage companies listed at the stock exchanges and discuss how to maintain a sustainable life science capital market in the Nordics.
Part 1: From seed to IPO: the stages of StartUp fundraising
Part 2: Stockholm, the capital of IPOs (IPOs as exit possibility for VCs)
Part 3: Maintaining a sustainable life science capital market in the Nordics
Hosted by:
DNB
Nasdaq
Novo Holdings
Industrifonden
Sponsored by:
DNB
Moderator(s): Dr. Sonja Benhamida - Senior Vice President Healthcare, DNB
Speaker(s):
Dr. Thomas Grotkjaer
-
Principal, Novo Holdings
Mr. Thomas Gidlund
-
Investment Manager, Sciety
Mr. Ari-Pekka Laitsaari
-
Growth Capital and Innovation Finance, European Investment Bank
Mr. Shutian Liu
-
Managing Partner and Founding Partner, Button Capital
Mr. Adam Kostyal
-
Senior Vice President, Nasdaq OMX
Mr. Patrik Ling
-
Senior Analyst HealthCare, DNB Markets
Dr. Patrick Sobocki
-
Investment Manager, Industrifonden